Showing 1951-1960 of 4063 results for "".
- Skye Fails Phase 2 Glaucoma Trial; Shifts Focus to Obesityhttps://modernod.com/news/skye-fails-phase-2-glaucoma-trial-shifts-focus-to-obesity/2482317/Skye Bioscience announced that its phase 2a clinical trial of SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering IOP. As a result, Skye intends to discontinue clinical development and spendi
- Vision Source Wins $2 Million Contract for Achievements in Value-Based Carehttps://modernod.com/news/vision-source-wins-2-million-contract-for-achievements-in-value-based-care/2476745/Southern New England Practice Transformation Network (SNE-PTN) will be awarding over 1,100 select Vision Source member practices achievement payments of up to $2,500 per practice for their performance in the transformation towards value-based care in 2019. Vision Source member practices co
- Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposiumhttps://modernod.com/news/abstract-on-zeta-1-study-of-apx3330-receives-award-at-women-in-ophthalmology-wio-summer-symposium/2481795/Ocuphire Pharma announced that data from its phase 2 clinical trial of APX3330 in diabetic retinopathy (DR) were featured in an oral presentation on Saturday, August 26 at the
- The Vision Council Opens Registration for 2026 Executive Summithttps://modernod.com/news/the-vision-council-opens-registration-for-2026-executive-summit/2484153/The Vision Council announced that registration is open for the 2026 Executive Summit. The 3-day forum will be held January 26-28, 2026, at The Ritz-Carlton, Amelia Island, Florida.
- Prevent Blindness Issues Statement on Proposed Legislation That Includes a $2M Cut to the CDC’s Vision Health Initiativehttps://modernod.com/news/prevent-blindness-issues-statement-on-proposed-legislation-that-includes-a-2m-cut-to-the-cdcs-vision-health-initiative/2485432/Key Takeaways The FY 2026 appropriations bill cuts $2 million from the
- Coave Therapeutics Announces Positive 12-Month Data from Ongoing Phase 1/2 Clinical Trial of Investigational RP Drughttps://modernod.com/news/coave-therapeutics-announces-positive-12-month-data-from-ongoing-phase-12-clinical-trial-of-investigational-rp-drug/2481640/Coave Therapeutics announced positive 12-month results from its phase 1/2 trial evaluating the safety and efficacy of its gene therapy, CTx-PDE6b, for retinitis pigmentosa (RP) caused by bi-allelic mutations in the PDE6B gene (PDE6b RP). These positive data support C
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-low-dose-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481334/Viridian Therapeutics announced positive topline clinical data from the third, low dose cohort in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). The company said it believes
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481240/Viridian Therapeutics announced positive topline clinical data from the first two cohorts in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). TED is a rare autoimmune disease in which the body’s own immune sys
- Oculis Announces Positive Data From Two Proof-of-Concept Phase 2 Trials With OCS-02 in Dry Eye Disease and Acute Anterior Uveitishttps://modernod.com/news/oculis-announces-positive-data-from-two-proof-of-concept-phase-2-trials-with-ocs-02-in-dry-eye-disease-and-acute-anterior-uveitis/2479192/Oculis announced positive data from two clinical proof of concept phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in dry eye disease (DED) and acute anterior uveitis (AAU). The data were presented for the first time at ARVO 2021, the annual meeting of th
- Saunders Finds Life After Allergan on Board at Newly IPO’ed BridgeBiohttps://modernod.com/news/saunders-finds-life-after-allergan-on-board-at-newly-ipoed-bridgebio/2477933/Less than 2 months after Allergan was officially taken in by AbbVie, its last helmsman, Brent Saunders, has landed on the board of a young biotech that recently pulled off a large IPO, according to a FiercePharma